NextCure Delays LNCB74 Proof-of-Concept Data as SIM0505 Advances

Event summary

  • NextCure anticipates Q2 2026 Phase 1 dose escalation data for SIM0505 (CDH6 ADC) in gynecological cancers.
  • LNCB74 (B7-H4 ADC) Phase 1 trial expanded to higher dose cohorts, delaying proof-of-concept data to H2 2026.
  • Company reports $41.8M cash position as of December 31, 2025, with runway into H1 2027.
  • SIM0505 clinical sites and drug supply being increased for dose optimization in H1 2026.

The big picture

NextCure's updates reflect the high-stakes balancing act of advancing two ADC programs with distinct mechanisms. While SIM0505's progress aligns with NextCure's focus on gynecological cancers, LNCB74's delay underscores the challenges of dose optimization in diverse tumor types. The company's cash runway provides breathing room, but investors will scrutinize whether these programs can deliver differentiated efficacy to attract partners or buyers.

What we're watching

Clinical Momentum
Whether SIM0505's Q2 2026 data will validate its broad anti-tumor potential in platinum-resistant ovarian cancer.
Execution Risk
The pace at which LNCB74 can enroll higher dose cohorts to meet revised H2 2026 proof-of-concept timelines.
Financial Flexibility
How NextCure will allocate its $41.8M cash position to sustain operations through H1 2027.